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ABSTRACT 
Regulation of folate and methyl group metabolism is essential in the prevention of a 
number of pathologies including vascular disease, cancer, and neural tube defects. 
Understanding the control of the enzyme glycine N-methyltransferase (GNMT) and other key 
enzymes in methyl group metabolism is critical for disease prevention. Both nutritional and 
hormonal factors have been identified as having the ability to modulate folate, methyl group, 
and homocysteine metabolism. Specifically, both glucocorticoids and/or all-trans-retinoic 
acid (RA) have shown to induce active GNMT protein. This study was conducted to 
determine how a diabetic state, alone and in combination with RA-treatment, altered methyl 
group metabolism. GNMT activity increased 87% and 148% with diabetes and RA 
treatment, respectively. This induction of GNMT activity by diabetes and RA was also 
reflected in the abundance of the protein. In cell culture studies, pretreatment with insulin 
prevented the induction of GNMT by RA and dexamethasone. A decrease in homocysteine 
concentrations was exhibited in diabetic rats, possibly as a result of a 38% increase in the 
abundance of the cystathionine ~-synthase (CBS) which commits homocysteine to 
catabolism. Treatment of diabetic rats with RA prevented the induction of CBS. A diabetic 
state and RA-treatment seemed to rely on different remethylation mechanisms. Folate-
independent remethylation enzyme betaine-homocysteine S-methyltransferase (BHMT) 
increased in a diabetic state. Conversely, RA administration caused an increase in activity of 
the folate-dependent enzyme, methionine synthase (MS), but did not reach significance. 
These results indicate that both a diabetic condition and RA treatment cause significant 
alterations in the metabolism of methyl groups and homocysteine, a finding that may have 
implications for diabetics and the potential for complications associated with retinoid use. 
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CHAPTER 1 - GENERAL INTRODUCTION 
Thesis Organization 
The contents of this thesis are organized into several chapters. Chapter 1 is an 
introduction giving the reader an idea of the research questions the author focused on. A 
broad review of the literature constitutes Chapter 2 including information that is pertinent to 
the author's research in folate and methyl group metabolism. Chapter 3 contains research 
submitted to the Journal of Biochemistry exploring the factors, diabetes and retinoid 
treatment, in folate and methyl group metabolism. General conclusions and ideas for future 
research are incorporated into chapter 4, followed by a complete list of the literature 
referenced throughout this thesis. 
Description of the Research Questions 
The interrelated folate, methyl group, and homocysteine pathways function to carry 
and activate one-carbon units in the formation of essential biological compounds throughout 
the body. Specifically, these mechanisms are vital in the production of nucleic acids, 
proteins, phospholipids, and neurotransmitters. Therefore interruption of these pathways can 
result in a number of diseases including cancer, vascular disease, and neural tube defects. 
A number of factors have been identified as having the ability to alter folate, methyl 
group, and homocysteine metabolism. Our laboratory has demonstrated that the vitamin A 
derivative all-trans-retinoic acid (RA) disrupts methyl group metabolism by activating the 
enzyme glycine N-methyltransferase (GNMT) as well as increasing protein abundance in 
vitro and in vivo, which in turn leads to loss of methyl groups for SAM-dependent 
transmethylation reactions (Rowling and Schalinske 2001; Rowling and Schalinske 2003). 
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Moreover treatment with RA has shown to cause hypomethylation of DNA (Rowling et al., 
2002). RA has also been indicated in the transcriptional induction of key enzymes in the 
gluconeogenic pathway including phosphoenolpyruvate carboxykinase (Pan et al., 1990; 
Shin and McGrane 1997). 
Several studies have also reported compounds that simulate a gluconeogenic state, 
including glucagon and glucocorticoids, which have the ability to modify folate, 
homocysteine, and methyl group metabolism. The Brosnan lab group found rats treated with 
glucagon exhibited elevated activities of GNMT and cystathionine ~-synthase (CBS), as well 
as decreased plasma homocysteine concentrations indicating increased flux through the 
transsulfuration pathway (Jacobs et al., 2001). Several studies conducted in diabetic-induced 
rats have also revealed similar modifications in one-carbon metabolism, whereas treatment 
with insulin seemed to prevent these alterations (Xue and Snoswell 1985; Jacobs et al., 1998; 
Ratnam et al., 2002). Finally, glucocorticoid administration results in the induction and 
activation of GNMT in cell culture and animal models (Rowling and Schalinske 2003) and 
increased cellular levels of CBS protein and CBS mRNA in vitro (Ratnam et al., 2002). 
Moreover, Rowling and Schalinske found that glucocorticoid treatment was just as effective 
as RA in inducing GNMT (2003). Based on the aforementioned evidence, the goal of our 
study was to determine how a diabetic state and RA, alone or combined, effect methyl group 
metabolism. 
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CHAPTER 2 - LITERATURE REVIEW 
Folate Metabolism 
Structure and Function of Folate Compounds 
Structure 
Folate, a generic term for a family of essential water soluble B-vitamins, functions 
primarily to accept and donate one-carbon units in vital metabolic pathways throughout the 
body (Bailey and Gregory 1999a; Lucock and Daskalakis 2000). This family of vitamins, 
also known by the chemical name pteroylglutamic acid, contains both natural and synthetic 
forms all of which are similar in structure. The basic structure of folate moieties consists of a 
pteridine ring, p-aminobenzoic acid, and one or more glutamic acid residues linked by y-
carboxyl peptide bonds (Figure 2.lA). Folate forms differ by altering the structure in three 
follc add 
Figure 2.lA. Basic structure of folate molecules (modified from van der 
Put et al. , 2001 ). 
locations: modifying the reduction state of the pteridine ring, adding one-carbon units at the 
N5 and/or N 10 binding sites (Figure 2.lB), or varying the number of glutamic acid residues 
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attached. Naturally occurring folate is typically polyglutamated containing between three and 
seven glutamyl residues and exists most commonly as 5-methyltetrahydrofolate (5-CH3 THF) 
and 10-formyltetrahydrofolate (10-CHO-THF). The synthetic form of folate, folic acid used 
in supplements and fortified foods, is monoglutamated (van der Put et al., 2001). 
~ N"' 
-CH1 -H S"Wtlh)J ~ 
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Figure 2.lB. Folate derivatives (modified from van der Put et al., 2001) 
Function 
The donation of one-carbon units is essential in the production of nucleic acids (DNA 
and RNA), proteins, as well as in the metabolism of amino acids. These one-carbon units 
exist at various oxidation levels, as seen in figure 2. lB, and the reactions they are involved in 
are collectively known as folate-dependent one-carbon metabolism (Wagner 1995). The 
reduced folate derivative, tetrahydrofolate (THF), accepts one-carbon units at the oxidation 
level of formate from histidine degradation, or at the oxidation level of formaldehyde from 
the third carbon of serine (Shane and Stokstad 1985). However, one-carbon units can also be 
derived from glycine, dimethylglycine (DMG), and methylglycine (van der Put et al., 2001). 
Specifically folate, in the form of 10-CHO-THF, is needed to donate carbon 2 and 8 in the 
5 
purine component of DNA (Figure 2.2). The folate derivative, 5,10-
methylenetetrahydrofolate (5, 10-CH2 THF), is involved in the biosynthesis of the pyrimidine 
building block of DNA (Shane and Stokstad 1985; Wagner 1995; Scott and Weir 1998). 
Aside from the role of folate in the biosynthesis of nucleic acids, one-carbon units provided 
by folate are used in over one hundred methyltransferase-catalyzed reactions (van der Put et 
al., 2001) (Figure 2.3). 
~nr:(C} 
Figure 2.2. The role folate in purine and pyrimidine biosynthesis (from 
Scott and Weir 1998). 
Folate Utilization 
Digestion and Absorption 
® 
Mammals are unable to synthesize folates de novo, making it necessary to attain 
folate compounds through consumption (Shane 1995). The polyglutamated chain of 
naturally occurring folates must be removed before the vitamin is digested. Excess glutamate 
residues are hydrolyzed by the enzyme y-glutamyl hydrolase in brush border mucosal cells of 
the proximal small intestine, and in turn this monoglutamated form is absorbed (McDowell 
6 
2000). Typically if the folate compound is not already in the form of 5-CH3 THF, it will be 
converted to this form and transported through the intestinal mucosa cell (Scott 1999). The 
monoglutamated synthetic form of folate is readily absorbed, primarily in the jejunum. 
Transport and Storage 
Following absorption, folate passes through the mucosal cell and is taken up by the 
liver via portal circulation (Shane 1995). In the liver, folate remains in the form 5-CH3-THF 
or is otherwise converted to 10-CHO-THF and transported to peripheral tissue (McDowell 
2000). The transport of folate into cells can be accomplished by one of three mechanisms: (i) 
unidirectional transport by membrane-bound folate-binding proteins/receptors, (ii) 
bidirectional internalization by carrier-mediated reduced folate carriers, (iii) or by passive 
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Figure 2.3. Folate and one-carbon metabolism (from Scott and Weir 1998) 
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diffusion (Sirotnak and Tolner 1999; Suh et al., 2001). Once folate enters the cell the 
enzyme methionine synthase (MS) converts 5-CH3 THF to THF the favored substrate of the 
enzyme, folylpolyglutamate synthase. The activity of this enzyme, necessary to retain folate 
within the cell, results in the polyglutamylation of THF and is present in both the 
mitochondria and cytoplasm (Lucock and Daskalakis 2000). 
Polyglutamylated folate is compartmentalized between the cytoplasm and the 
mitochondria (Cook and Blair 1979). Most folate in the cell is protein-bound and usually 
remains in their respective compartment; however the products that result from folate 
compounds are easily transferred between the cytoplasm and mitochondria (Lin and Shane 
1994). At any time cellular concentrations of free folate are negligible due to tight-binding 
proteins, which also limits intracellular folate accumulation when saturated (Matherly et al., 
1990). The body typically stores between 5 and 10 mg of folate, half of which is found in the 
liver in the form of 5-CH3THF (Herbert 1999). 
Degradation and Excretion 
Protein-bound folates are stable compared to free-folate, which are often depleted in 
the cell due to their instability. There are three mechanisms that are thought to cause the 
turnover of folates, specifically unbound folate: exit of folate molecules from lack of 
polyglutamylation, folate polyglutamates are hydrolyzed to monoglutamates by y-
glutamylhydrolase and exit the cell, or folate catabolism (Suh et al., 2001). A majority of 
folate excretion is in feces via bile due to enterohepatic circulation most of which is 
reabsorbed in the intestine. However, a small portion of excreted folate can be found in urine 
following glomerular filtration and reabsorption of some of the folate (Herbert 1999). 
Degradation of folate generates pteridines and acetaminobenzoylglutamate. 
Dietary Requirements 
Sources of Folate 
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Currently recommendations for folate intake are focused on reducing the risk of 
chronic disease, which means maintaining optimal one-carbon metabolism (Boushey et al., 
1995). Folates are present in most natural foods with fruits and vegetables being the richest 
sources. Specifically, spinach, brussel sprouts, potatoes, oranges, beans, and liver, are 
excellent sources of folate (Bailey 1995; van der Put et al., 2001). However, these natural 
forms of folate are particularly susceptible to oxidative damage, and it is estimated that 50-
95% of the folate is destroyed by cooking excessively (Herbert 1999). There are also several 
states in the body that can result in altered folate status and increased catabolism and in turn 
increases folate requirement such as pregnancy, oral contraceptive or anticonvulsant use, 
cancer, or chronic alcohol consumption (Suh et al., 2001 ). It is because of this potential for 
folate deficiency and the risk of congenital defects as well as chronic disease associated with 
deficiency that the U.S. Food and Drug Administration made it mandatory for enriched grain 
products to include folic acid ( 1996). This fortification has led to a decline in the prevalence 
of folate deficiency-related pathologies specifically neural tube defects (Honein et al., 2001). 
Recommended Intake 
Folate dietary requirements are expressed as recommended dietary allowances (RDA) 
which is derived from the estimated average requirement (EAR) as well as adjusting to meet 
the requirements for approximately 98% of the population. The EAR is defined as the 
amount needed to meet only 50% of the population (Bailey and Gregory 1999a). Given that 
synthetic folate is much more readily available than dietary folate, dietary reference intakes 
(DRis) for folate are expressed as dietary folate equivalents (DFE). One DFE is equivalent 
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to 1 µg of food folate, 0.6 µg of synthetic folate from fortified food or a supplement with 
food, or 0.5 µg of a supplement on an empty stomach (Food and Nutrition Board 2000). 
RDAs vary depending on age and state with males and females older than 14 years 
recommended to take in 400 µg DFE per day. The RDA declines for children less than 14 
years old to between 65 and 80 µg DFE per day in infants up to 12 months old. Folate 
requirements increase in the case of pregnancy and lactation at 600 and 500 µg DFE per day 
respectively (Table 2.1). This elevated requirement is due to the increased need for folate in 
Table 2.1 
Folate dietary reference intakes1 
Recommended 















modified from Bailey and Gregory 1999 
2 male and female 
65 
80 








cell division and increased clearance of folate during pregnancy, as well as the loss of folate 
in daily lactation following pregnancy (Bailey 1995). There are also upper limits (UL) 
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specified for each age group, meaning the maximum daily intake without inducing adverse 
effects. In children up to 8 years old the UL is 300-400 µg DFE per day and 600-800 µg 
DFE per day in males and females up to the age of 18 years old. The UL for adults above 19 
years old increases to 1,000 µg DFE per day in both males and females regardless of 
pregnancy and lactation (Food and Nutrition Board 2000). 
Methyl Group Metabolism 
Functions and Components of the Metabolic Pathway 
Transmethylation 
Methyl group metabolism functions in activating methyl groups provided to over one 
hundred methyltransferase reactions necessary for normal growth and development. Methyl 
group metabolism begins with the set of reactions collectively called transmethylation which 
relies on a supply of the essential sulfur-containing amino acid, methionine (Finkelstein 
1990). Methionine is converted to its activated form, S-adenosylmethionine (SAM) 
following adenylation. This reaction is catalyzed by the enzyme methionine 
adenosyltransferase (MAT) at the expense of ATP (Cantoni 1977; Chiang et al., 1996; Lieber 
and Packer 2002). At this point SAM, the primary methyl donor in most mammals, can 
donate activated methyl groups to many methyltransferase reactions in the modification and 
synthesis of essential molecules resulting in S-adenosylhomocysteine (SAH) (Mudd 1963; 
Mason 2003). The formation of creatine from guanidinoacetate seems to constitute a major 
use of methyl groups (Stipanuk 1986). However most SAM-dependent transmethylation 
reactions are inhibited by SAH, therefore it essential to regulate the SAM to SAH ratio as 
well as remove SAH to preserve methyl groups (Cantoni et al., 1978). 
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The folate-binding protein, glycine N-methyltransferase (GNMT), is believed to 
function in regulating the availability of SAM (Cook and Wagner 1984; Yeo and Wagner 
1994). GNMT is found in the liver, pancreas, and kidney, and comprises approximately 1 to 
3 % of all soluble hepatic cytosolic protein (Kerr 1972; Ogawa and Fujioka 1982). GNMT 
was found to be most abundant in the periportal region of the liver, the proximal convoluted 
tubules of the kidney, and the exocrine tissue of the pancreas (Yeo and Wagner 1994). This 
methyltransferase is an alternative mechanism for converting SAM to SAH, utilizing glycine 
and forming sarcosine, which currently has no known metabolic role (Kerr 1972; Heady and 
Kerr 1973). GNMT optimizes the SAM: SAH ratio, which is an indicator of 
transmethylation potential, given SAH is a potent inhibitor of most SAM-dependent 
methyltransferases (Yeo and Wagner 1994 ). 
Transmethylation results in the production of homocysteine following the removal of 
adenosine from SAH. This exclusive metabolic pathway is catalyzed by S-
adenosylhomocysteine hydrolase (SAHH) (Cantoni and Chiang 1980). This reaction is 
reversible favoring SAH production, and sways in the opposite direction if adenosine and 
homocysteine can be efficiently removed (de la Haba and Cantoni 1959; Cantoni and Chiang 
1980) (Figure 2.4). 
Remethylation 
Two pathways exist that function to metabolize homocysteine: remethylation, 
recycling methyl groups in formation of methionine, or catabolism through transsulfuration 
forming cystathionine (Eloranta et al., 1990; Lieber and Packer 2002). Homocysteine can be 
remethylated through both folate-dependent and folate-independent mechanisms, both 
pathways contributing equally to the formation of methionine (Finkelstein and Martin 1984 ). 
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In hepatic tissue and possibly kidney, betaine derived from the oxidation of choline, serves as 
a source of methyl groups in the remethylation of homocysteine via the enzyme betaine-
homocysteine S-methyltransferase (BHMT) (Finkelstein et al., 1971). This folate-
independent route results in methionine and DMG (Sunden et al., 1997). 
Alternatively, remethylation occurs with the donation of a methyl group by 5-







Cysteine, Glutathione, Taurine, Pyruvate 
Figure 2.4. Folate, methyl group, and homocysteine metabolism 
and Martin 1984 ). Upon donation of a methyl group in the remethylation of homocysteine, 
5-CH3 THF is reduced to tetrahydrofolate (THF) (Wagner 1995). At this point THF can 
either be reversibly converted to 10-CHO-THF and donate its one-carbon units in the 
formation of purines, or combine with serine to form 5, 10-CH2 THF and glycine. This 
reaction is reversible catalyzed by the enzymatic activity of serine hydroxymethyltransferase 
(SHMT), which is dependent on vitamin B6 as a coenzyme (Schirch and Strong 1989). One-
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carbon units from 5,10-CH2THF, can then be donated to deoxyuridine monophosphate 
(dUMP) in formation of the DNA precursor, thymidylate via the catalytic activity of 
thymidylate synthase (TS) (Scott and Weir 1998) (Figure 2.4). 
The folate compound 5,10-CH2THF, is also used in the synthesis of 5-CH3THF, 
which is irreversibly catalyzed by the enzyme 5,10-methylenetetrahydrofolate reductase 
(MTHFR), a riboflavin-dependent enzyme. At any given time the concentration of free folate 
compounds in the cell is insignificant leading to a struggle for folate compounds between 
folate binding proteins, such as MTHFR and TS (Schirch and Stong 1989; Strong et al., 
1990; Suh et al., 2001 ). The enzyme SHMT provides a regulatory mechanism for 
distribution of one-carbon units between thymidylate and methionine synthesis that when in 
excess favors thymidylate. This favoring is accomplished by binding and sequestering 5-
CH3 THF which in tum prevents the remethylation of methionine (Herbig et al., 2002). 
Transsulfuration 
Catabolism of the sulfur-containing amino acid homocysteine occurs through a group 
of reactions known as transsulfuration. Major enzymes involved in this pathway, 
cystathionine ~-synthase (CBS) and y-cystathionase, are vitamin B6-dependent. The first 
committed step, converting homocysteine to cystathionine is catalyzed by CBS which utilizes 
serine in a condensation reaction (Kutzbach and Stokstad 1971; Krebs et al., 1976). Finally, 
cystathionine is converted to the amino acid cysteine as well as other useful metabolites: 
glutathione, taurine, and pyruvate (Stipanuk et al., 1992). The enzyme y-cystathionase 
initiates this final step of the transsulfuration pathway (Stipanuk 1986). Transsulfuration 
does not occur ubiquitously, with some cells lacking part or the entire pathway (Finkelstein 
et al., 1971). 
Regulation of Methyl Group Metabolism 
Allosteric Regulation 
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In order to make certain there is an adequate supply of methyl groups for SAM-
dependent transmethylation reactions a number of regulatory mechanisms exist. The enzyme 
GNMT is subject to allosteric regulation based on the supply of methyl groups, in the form of 
SAM, to optimize the SAM to SAH ratio (Ogawa and Fujioka 1982). In the state of excess 
methyl groups through the diet or the folate-dependent one-carbon pool excess SAM binds to 
MTHFR, inhibiting enzyme activity (Jencks and Matthews 1987) (Figure 2.5). This 
inhibition reduces the synthesis of 5-CH3 THF and in turn alleviates the allosteric inhibition 
5-CH3 THF inflicts upon GNMT resulting in the disposal of excess methyl groups. 
Conversely, in the state of methyl group deficiency, reduced circulating SAM concentrations 
results in increased activity of MTHFR elevating concentrations of 5-CH3 THF. Further, 5-
CH3 THF allosterically inhibits GNMT thereby providing methyl groups for SAM-dependent 
transmethylation reactions (Wagner 1985). 
In addition to regulating methyl group supply through the enzymes MTHFR and 
GNMT, there are a few other points of control. Specifically, SAM is a positive allosteric 
regulator of CBS, the enzyme that commits homocysteine to the transsulfuration pathway 
(Finkelstein et al., 1975). Excess circulating SAM concentrations will activate CBS resulting 
in the normalization of methyl group supply by increasing catabolism. Secondly, excess 
dietary protein ensuing elevated SAM concentrations will restrict remethylation enzyme 
BHMT, again to bring methyl group supply to an optimal state (Finkelstein and Martin 
1984 ). However if methionine is restricted, BHMT gene expression is enhanced, conserving 
methyl groups (Park et al., 1997). 
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Hormonal Regulation 
Specific hormones have been identified as having the ability to modulate methyl 
group metabolism. A diabetic state characterized by insufficient circulating insulin and 
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Figure 2.5. Regulation of methyl group metabolism 
elevated counterregulatory hormones (e.g. glucagon, and glucocorticoids) has been indicated 
in directly altering enzymes involved in methyl group metabolism. In a study by Xue and 
Snoswell, a 65-fold induction in GNMT activity was reported in alloxan-induced diabetic 
sheep (1985). Similarly, in an alloxan-induced diabetic state or a starvation state in rats, 
resulted in a 2-fold induction in GNMT activity (Yeo and Wagner 1994). 
Modifications in homocysteine concentrations are also evident in the diabetic state, 
but appear to be dependent on the status of the kidneys (Bostom and Culleton 1999; 
16 
Wolleson et al., 1999). If renal function is sufficient, a diabetic condition results in a marked 
decrease in plasma homocysteine concentrations. However, if diabetes is coupled with renal 
dysfunction, the outcome is elevated plasma homocysteine levels (Poirier et al., 2001 ). 
Elevated homocysteine is an independent risk factor for vascular disease, which is considered 
to be the major cause of death in diabetics (Renold et al., 1978). In a study by Jacobs et al., 
researchers examined this effect in streptozotocin-induced rats and found plasma 
homocysteine concentrations were reduced by 40%; however treatment with insulin 
prevented the decrease in homocysteine, indicating insulin may be involved in the regulation 
(1998). 
It seems that this decline in homocysteine manifests through the modification of 
transsulfuration enzymes, cystathionine P-synthase and y-cystathionase. As presented in a 
later study by Jacobs et al., a state of hyperglucagonemia in rats induced activity of CBS, y-
cystathionase, and increased CBS mRNA levels (2001). The study also revealed increased 
concentrations of SAM and SAH, which are allosteric activators of CBS, indicating an 
increase flux through the transsulfuration pathway (Jacobs et al., 2001). Further, 
streptozotocin-induced diabetic rats in a study by Ratnam et al. revealed clearly elevated 
CBS mRNA which was reduced by insulin administration (2002). 
Similarly, glucocorticoids have shown to modulate key enzymes in methyl group 
metabolism. In rat hepatoma cells, CBS protein abundance as well as CBS mRNA levels 
were increased following treatment with the synthetic glucocorticoid, triamcinolone. This 
effect occurred by stimulating gene expression at the transcriptional level, and the 
stimulatory effect was prevented by insulin treatment (Ratnam et al., 2002). Moreover, 
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treatment with the glucocorticoid dexamethasone has shown to induce GNMT activity and 
protein abundance in rats and rat hepatoma cells (Rowling and Schalinske 2003). 
Dietary Requirements 
A sufficient supply of methyl groups through the diet, from choline and/or 
methionine, or as a result of the folate-dependent one-carbon pool is necessary for growth 
and development (Finkelstein and Martin 1986). Currently, only estimates exist for 
methionine requirements based on nitrogen balance studies, which tend to be group with the 
other sulfur-containing amino acid, cysteine. The estimates for methionine/cysteine 
requirements in mg/kg/day are classified by age as follows: 3-4 months, 158; 2-5 years, 27; 
10-12 years, 22; greater than 12 years, 13 (Matthews 1999). It is definitely necessary to 
fulfill protein requirements, however excessive methionine can be toxic (Benevega and 
Steele 1984 ). The incorporation of choline into a low-protein diet at methyl loads at the 
same level or greater than methionine seems to reduce the adverse effects seen with 
methionine (Case et al., 1976). Conversely, there is an adequate intake and UL stated for 
choline in the current DRis. Adequate intake is given in µg/day and classified by age as 
follows: 0-12 months, 125-150; 1-8 years, 200-250; 9-13 years, 375; males greater than 14 
years, 550; females 14-18 years, 400; females greater than 18 years, 425. A slightly elevated 
choline recommendation exists for pregnant or lactating women at 450 and 500 µg/day, 
respectively (Food and Nutrition Board 2000). 
Disruptions in Folate and Methyl Group Metabolism 
Folate and methyl groups are directly or indirectly involved in cell function, division, 
and differentiation, thus necessary for essential biological processes. Therefore insufficient 
supply of folate, methyl groups, or related cofactors (vitamin B6 and B12) can result in a 
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multitude of pathologies as a result of disruptions in methyl group metabolism. In addition to 
nutrient deficiencies, treatment with retinoid compounds has shown to perturb methyl group 
metabolism. Lastly, individuals that possess genetic polymorphisms in key enzymes 
involved in these interrelated pathways may cause alterations and susceptibility to associated 
pathologies. 
Neural tube defects 
Folate and methyl group metabolism are critical components in fetus development 
given that one-carbon units are needed in the synthesis of DNA, protein, and phospholipids 
(Chiang et al., 1996). Neural tube defects (NTDs) are characterized by malformation of the 
brain and/or spinal cord in the developing embryo, instigating incomplete central nervous 
system development (van der Put et al., 2001). NTDs are one of the most common birth 
defects occurring in 1 in 1000 births in the United States (Center for Disease Control and 
Prevention 1996; AAP Committee on Genetics 1999). 
The most common manifestations of NTDs are as congenital disorders, spina bifida 
and anencephaly, accounting for 50 and 40% of cases, respectively (Scott et al., 1995). 
Spina bifida is distinguished by incomplete closure of the spinal cord (posterior end of the 
neural tube) causing physical disabilities in the child. Conversely, anencephaly results in 
incomplete closure of the skull (anterior end of the neural tube) and is incompatible with life 
(Green 2002). The etiology of NTDs is continually evolving but not yet clearly understood, 
with over 90% of NTD cases occurring from unknown causes (van der Put et al., 2001). 
Identified origins of NTDs have been classified as both genetic and environmental with 
nutritional deficiency, specifically folate, being one of them (Lucock and Daskalakis 2000). 
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Folate status has long been examined for its role in NTDs, with earlier studies 
reporting associations between fetal malformations and folate deficiency (Hibbard 1964 ). 
Further interactions between NTDs and folate were found in study that reported low folate 
stores in women with pregnancies affected by NTDs, in turn suggesting periconceptional 
folate supplementation might protect against NTDs (Smithells et al., 1976). Elucidating the 
specific mechanism by which folate supplementation prevents NTDs is ongoing; however 
data currently exists supporting the beneficial role of folate supplementation in reducing the 
occurrence of NTDs. In particular, it was shown that folic acid treatment alone was just as 
effective in preventing NTDs as a multivitamin with folate (Medical Research Council 
1991). Moreover, a study involving 4,000 women reported 6 cases of NTDs in women 
receiving a placebo multi-mineral, as compared to no incidences of NTDs in the other group 
of women given a multivitamin containing folic acid (Cziezel and Dudas 1992). In addition, 
recent reports suggest an inverse relationship between methionine intake (Shoob et al., 2001) 
and vitamin B12 status (Schorah et al., 1980; Kirke et al., 1993), on the prevalence of NTDs. 
In response to the building evidence of the effectiveness of folic acid in the prevention of 
NTDs, the Center for Disease Control recommended any woman of child-bearing age 
consume at least 400 µg of folic acid per day ( 1991 ). 
Hyperhomocysteinemia 
Clearance of the non-protein-forming amino acid, homocysteine is dependent on 
remethylation and transsulfuration pathways and is possibly regulated nutritionally (Selhub 
1999). SAM seems to be a key regulator in homocysteine metabolism since SAM 
allosterically inhibits MTHFR and BHMT and activates CBS. Folate as well vitamins B6 and 
B12 are also key factors in homocysteine metabolism. Deficiency in any of these nutrients 
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can result in the disruption in homocysteine metabolism, and in tum hyperhomocysteinemia 
(Green and Jacobsen 1995). 
Hyperhomocysteinemia is positively associated with vascular diseases and has been 
recently added to the list of commonly known risk factors for cardiovascular disease (CVD) 
(Selhub and Miller 1992; Selhub et al., 1995; Lee and Wang 1999). An elevation in plasma 
homocysteine concentrations by as little as 1 µmol/L is associated with a 10% increase in the 
risk of CVD (Blom 1998). Severe hyperhomocysteinemia can result from inborn errors in 
enzymes necessary for clearance of homocysteine, specifically CBS, MTHFR, and MS 
(Clarke 1991; Selhub 1999). Folate deficiency has also been linked to elevated plasma 
homocysteine, with a 9.8-fold increase reported in folate-deficient rats as compared to 
folate-replete controls (Miller et al., 1994). A reduction in plasma homocysteine 
concentrations were also evident following administration of folic acid promoting 
remethylation (Brattstrom et al., 1988; Wilcken et al., 1988; Mason and Miller 1992; 
Pancharuniti et al., 1994). Therefore it is estimated that increasing folate intake by 200 µg 
per day will result in a reduction in homocysteine by 4µmol/L (Boushey et al., 1995; van 
Oort et al., 2003). 
Research is ongoing as to whether homocysteine actually imposes atherogenic effects 
or if it just an indicator of another mechanism (Ueland et al., 2000). Many studies do support 
the hypothesis that homocysteine is directly involved in vascular disease by causing 
degeneration of the vascular endothelium (Lucock and Daskalakis 2000). Particularly, a 
study using cultured endothelial cells has demonstrated cytotoxic effects following 
homocysteine treatment (Wall et al., 1980). In addition an in vivo study revealed the rapid 
formation of plaques following injection of homocysteine thiolactone (McCully and 
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Ragsdale 1970). Additional mechanisms indicate homocysteine may induce vascular disease 
by causing platelet function abnormalities and endothelial dysfunction; however the exact 
mechanism is yet to be revealed. 
Finally, elevated homocysteine is consistently associated with NTDs which again 
may be as a result of inborn errors in the enzymes (MTHFR and MS) involved in 
remethylation of homocysteine (van der Put et al., 1995; Morrison et al., 1997). Further an 
association has been identified between NTD births and increased cellular folate depletion. 
This was thought to be a result of impaired folate remethylation to THF the main intracellular 
form of folate (Lucock et al., 1998). This further identifies the need to promote 
periconceptional vitamin supplementation, specifically folate. 
Cancer 
As explained previously, folate is directly and indirectly involved in the modification 
and synthesis of DNA. Therefore, folate deficiency has been identified as a factor 
contributing to cancer development and enhancement (Mason 1995). Mechanisms for this 
relationship have been proposed but not yet clearly defined (Bailey and Gregory 1999a). 
One hypothesis of this relationship is in the donation of one-carbon units from 5, 1 O-CH2 THF 
in the synthesis of the DNA precursor thymidylate. Inadequate folate can lead to 
misincorporation of uracil into DNA due to lack of thymidylate. This misincorporation can 
lead to stress of the DNA repair mechanism and in turn cause DNA strand breaks and 
chromosome instability. However misincorporation of uracil and subsequent DNA damage 
seems to be reduced by folate supplementation (Blount et al., 1997). 
Another proposed mechanism for this relationship between folate and cancer is the 
role of folate in DNA methylation. DNA methylation has shown to regulate gene expression, 
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with lack of methylation typically leading to gene expression, and increased methylation 
resulting in gene suppression (Wagner 1995). In addition to methyl groups being provided 
by protein in the diet, folate indirectly plays a role in methylation of DNA by donating a 
methyl group to homocysteine in the generation of SAM. Therefore, it has been observed 
that rats fed a diet lacking folate, methionine, choline, and vitamin B 12, display decreased 
SAM concentrations and hepatic DNA methylation (Wainfan et al., 1989). Global DNA 
hypomethylation has shown to precede cancer development, specifically due to 
hypomethylation of proto-oncogenes which increases transcription of associated mRNAs 
(Dizik et al., 1991 ). 
An additional hypothesis for the role of folate in cancer is in cytotoxic natural killer 
cells. Natural killer cells provide important immune protection against tumor cells 
(Trinchieri 1989). It was proposed that in folate deficiency these cells have reduced ability to 
destroy cancerous cells (Mason 1995). Further research suggests that natural killer cell-
mediated cytotoxicity is dependent on the state of folate deficiency with severe folate 
deficiency in rats resulting in the reduced ability for cytotoxicity. However moderate folate 
deficiency, associated with increased risk of some cancers, did not affect cytotoxicity 
capabilities of natural killer cells (Kim et al., 2002). 
Accumulating evidence suggests that folate may play a role in development and 
progression of many cancers including: colorectum, lungs, pancreas, esophagus, stomach, 
cervix, breast, and leukemia (Kim 1999). The most evidence of the relationship between 
folate and cancer development has been exposed in colorectal cancer (Prinz-Langenohl et al., 
2001; Kim 2003). Several retrospective studies have suggested a decreased risk of colorectal 
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neoplasms in subjects with the highest folate intake; whereas folate deficiency increases the 
risk of colorectal cancer (Bailey et al., 2003; Giovannucici 2002). 
Megaloblastic Anemia 
Disturbed DNA synthesis as a result of folate and/or B12 deficiency can result in the 
megaloblastic anemia. This form of anemia manifests in large, immature, abnormal, red 
blood cell precursors in the bone marrow and peripheral blood (Kasdan 2000). The role 
folate and vitamin B12 play in this pathology is in the pathway converting 5-CH3 THF to THF 
through the activity of MS (Savage and Lindenbaum 1995). In the case that there is vitamin 
B12 deficiency, MS activity is reduced essentially trapping methyl groups in the form 5-
CH3 THF. This "methyl trap" decreases the availability of folate coenzymes for purine and 
pyrimidine biosynthesis, which are needed for red blood cell division and differentiation 
(Shane and Stokstad 1985). 
This somewhat pseudo folate deficiency that occurs can result in a reduction of SAM 
and in tum methyl groups for transmethylation reactions including myelin basic protein. A 
decrease in methyl groups for synthesis of myelin basic protein can cause demyelination and 
in tum a state of neuropathy (Scott 1999). Therefore, it is crucial that individuals suffering 
from megaloblastic anemia not only supplement folate, but vitamin B12 to prevent associated 
neuropathy. However, steps should be taken to discover the root of the problem because 
supplementing folate can mask vitamin B12 deficiency and exacerbate associated 
neurological problems (Bottiglieri et al., 1995). 
Neurological/Neuropsychiatric Disorders 
Neurological disorders associated with folate and/or B 12 deficiency are not quite as 
well understood as the hematological disorders. Vitamin B12 and folate deficiencies have 
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been associated with neurological and neuropsychiatric disorders (Bottiglieri 1996). A 
hypothesis for the role of these nutrients is again through the reaction catalyzed by MS. MS, 
which utilizes both vitamin B12 and folate, in the formation of methionine and in tum SAM. 
SAM provides methyl groups in the synthesis of proteins, phospholipids and 
neurotransmitters such as serotonin, norepinephrine, and dopamine. Specifically reduced 
serotonin levels and activity have been reported in the brain of folate-deficient rats and 
humans (Hyland et al., 1988; Botez et al., 1979). It is interesting to note that 5-CH3THF is 
transported across the blood brain barrier, and the concentration in the cerebrospinal fluid is 
three times greater than in serum (Bottiglieri et al., 1995). This further indicates the 
importance of the MS-catalyzed pathway. 
Several studies have reported a high incidence of folate deficiency accompanying 
depression (Camey et al., 1990; Morris et al., 2003). Studies have also been conducted to 
determine the efficacy of folate and SAM supplementation in these affective disorders, 
whereas supplementation seemingly promotes antidepressant activity (Freida! et al., 1989; 
Godfrey et al., 1990). However it is not clear if folate deficiency actually plays a role in the 
development of depressive illnesses or if it is secondary to poor appetite. 
Recent studies have also linked the rise in homocysteine, resulting from folate 
deficiency and reduced enzyme activity, to two major neurological disorders: Alzheimer's 
disease and Parkinson's disease (Mattson and Shea 2003). Typically serum homocysteine 
levels are elevated in folate- or vitamin B12-deficient patients (Allen et al., 1993). There are 
several suspected mechanisms for the role of folate and homocysteine in neuronal damage. 
One of these mechanisms is folate deficiency is thought to induce DNA damage by reducing 
homocysteine remethylation to SAM for transmethylation reactions (Selhub and Miller 
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1992). Another possible mechanism is the accumulation of SAH. Elevated homocysteine 
creates a favorable condition for the hydrolysis of homocysteine to SAH by SAHH. SAH 
accumulation will inhibit SAM-dependent transmethylation reactions, and in turn induced 
DNA damage and cell apoptosis (Kruman et al., 2000). In addition, it has been shown that 
neurons cultured with homocysteine deplete their ATP reserves in attempts to repair 
damaged DNA. ATP depletion is thought to be a key factor in the degeneration of neurons in 
Alzheimer's and Parkinson's diseases (Kruman et al., 2000). 
Genetic Profile 
Genetic polymorphisms are among the factors that can perturb folate and methyl 
group metabolism resulting in associated pathologies. These genetic differences are in key 
enzymes in one-carbon metabolism and typically result in reduced activity. Several of these 
polymorphisms have been identified as well as the possible effects of their existence. 
MTHFR polymorphism 
The enzyme MTHFR catalyzes the irreversible conversion of 5,10-CH2THF to 5-
CH3 THF, which donates its methyl group in the remethylation of homocysteine. The most 
common mutation of this enzyme is autosomal recessive, occurring at base pair 677, and 
resulting in a c~T substitution (C677T) causing valine to substitute for alanine in the 
enzyme (Frosst et al., 1995). The frequency of this mutation varies depending on race and 
ethnic background, but it is estimated to occur at rate of 12% in Caucasian and Asian 
populations homozygous for the trait, and up to 50% for those who are heterozygous for the 
trait (Brattstrom et al., 1998). 
Individuals that are homozygous for this mutation exhibit reduced activity and 
stability of MTHFR. Studies indicate that persons with the homozygous C677T mutation 
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have reduced plasma folate concentrations and elevated plasma homocysteine concentrations 
(Brattstrom et al., 1998). Modest elevations in homocysteine is an independent risk factor 
for vascular disease and NTDs; however studies are conflicting as to whether the 
homozygous C677T mutation is itself a risk factor in vascular disease and NTDs (Bailey and 
Gregory 1999b ). The relationship between cancer and the homozygous C677T mutation 
seems to be dependent on folate status. A decreased risk for colorectal cancer was found in 
men with normal plasma folate concentrations and the MTHFR mutation by increasing the 
availability of one-carbon units for nucleotide synthesis. Conversely, the men with low 
folate status seemed to counteract the protective effect of the mutation (Ma et al., 1997). 
MS polymorphism 
The enzyme MS has also been identified in the list of mutations associated with one-
carbon metabolism. The most common MS polymorphism is located at base pair 2756 
causing an A~G (A2756G) substitution and resulting in glycine replacing aspartic acid in 
the functional enzyme (Chen et al., 1997). It is not yet clear whether this mutation changes 
activity or abundance of the enzyme; however most research indicates there is no association 
between this mutation and homocysteine concentrations (Hyndman et al., 2000; Klerk et al., 
2003). Most studies also indicate that there is no association between the homozygous 
mutation for MS and the risk for vascular disease (Ma et al., 1999; Morita et al., 1999; Tsai 
et al., 1999). Although a study by Kerk et al. did find that subjects homozygous for the MS 
mutation exhibited a four-fold increase in the risk of coronary heart disease as compared to 
individuals with the wild-type or heterozygous genotypes (2003). 
27 
CBS enzyme deficiency 
The transsulfuration pathway beginning, with the CBS activity, plays a crucial part in 
the removal of homocysteine when the supply of methyl groups is in excess (Finkelstein and 
Martin 1984 ). Therefore, when there is a deficiency in CBS activity both 
hyperhomocysteinemia and homocystinuria develop, and manifest in a number of 
pathologies (Selhub 1999). CBS enzyme deficiency is an autosomal recessive trait and the 
most common inborn error of methionine metabolism occurring in approximately 1 in 
200,000 individuals worldwide (Selhub and Miller 1992). Specifically, osteoporosis, 
scoliosis, arteriosclerosis, thromboembolism, convulsions, and psychiatric disturbances are 
some problems that can develop from this enzyme deficiency (Kluijtmans et al., 1999), and 
as many as 50% of those who go untreated, develop mental retardation (Yaghmai et al., 
2002). The exact mechanism by which CBS enzyme deficiency is associated with diseases is 
not yet known. 
Greater than 60 mutations have been identified in the CBS gene (Kraus 1998). The 
most severe mutations occur at base pair 833 resulting in a T ~c (T833C) substitution and at 
base pair 919 resulting in a G~A substitution (G919A). These mutations are fairly rare 
affecting less than 1 % of the general population (Klujtmans et al., 1996). The most common 
mutation is caused by a 68 base pair insertion between nucleotides 844 and 845 (844ins68). 
This mutation occurs in the heterozygous form in approximately 12 % of the U.S. population 
(Tsai et al., 2000). 
CBS is a vitamin B6-dependent enzyme, therefore some patients with CBS deficiency 
respond to vitamin B6 supplementation resulting in lower homocysteine concentrations. It is 
estimated that approximately 50% of those with CBS enzyme deficiency respond to high 
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doses of vitamin B6, evident by lowered homocysteine concentrations (Mudd et al., 1985). 
However, many individuals do not respond to vitamin B6 supplementation and therefore must 
rely on a methionine-restricted diet. Vitamins B12, B6, and folate may further reduce 
homocysteine concentration in these resistant individuals (Wilcken and Wilcken 1997). 
Betaine supplementation has also been tested in CBS deficient patients and has been found to 
consistently lower plasma homocysteine concentrations. The only concern is the elevated 
methionine levels that result, however most patients seem to remain below 1500 µmol/L, a 
level that has not been associated with adverse effects (Wilcken et al., 1983; Wilcken and 
Wilcken 1997). 
Retinoids 
Factors both nutritionally and hormonally have been identified as having the ability 
to alter methyl group metabolism by targeting key enzymes involved. Specifically the 
vitamin A derivatives, all-trans-retinoic acid (RA), and 13-cis-retinoic acid (CRA) are 
among these factors. More importantly these alterations may affect those who utilize these 
derivatives therapeutically. CRA (lsotretinoin/ Accutane®) is used in dermatology and 
currently taken orally to treat cystic acne that is unresponsive to topical treatment; whereas 
RA (Vesanoid®) is used in oncology to treat promyelocytic leukemia (Ohno et al., 2003; 
Peck et al., 1979). It is also interesting to note that the number of CRA prescriptions 
dispensed to treat cystic acne have increase 250% in the last decade (Wysowski et al., 2002). 
There are a number of side effects that can result from the therapeutic use of 
retinoids. Aside from CRA being a known teratogen, the most common side effect of 
retinoid administration is dyslipidemia resulting in elevated plasma lipid concentrations 
(Bershad et al., 1985). Approximately 90% of the vitamin A in the body is stored in the 
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liver, so excessive vitamin A can lead to liver abnormalities (Roenigk 1988). Administration 
of CRA in rats has also revealed accumulation of hepatic lipids in addition to elevated serum 
triglycerides (Schalinske and Steele 1993). Retinoid administration has shown to effect one-
carbon metabolism by increasing methionine catabolism as well as inducing hypomethylation 
of DNA by activating GNMT in rats (Fell and Steele 1986; Schalinske and Steele 1991; 
Rowling et al., 2002). An additional study also found elevated homocysteine concentrations 
in humans treated with isotretinoin, linking this finding to either CBS inhibition or liver 
dysfunction (Schulpis et al., 2001) 
CRA and RA have shown to induce GNMT activity and protein abundance in vivo 
(Rowling and Schalinske 2001; McMullen et al., 2002; Ozias and Schalinske 2003) as well 
as induction of GNMT by RA in vitro (Rowling and Schalinske 2003). Induction of GNMT 
results in a loss of methyl groups for subsequent SAM-dependent transmethylation reactions. 
This effect seems to be dose-dependent with as little as 5 µmol/kg body weight and a single 
dose causing significant induction and a maximal effect at 30 µmol/kg body weight and four 
days of treatment (Ozias and Schalinske 2003). Activation of GNMT by retinoids also 
exhibited tissue and gender specificity. McMullen et al. reported male rats were more 
sensitive to retinoid-mediated activation of GNMT than female rats (2002). Retinoid 
administration resulted in elevated hepatic GNMT protein and abundance, but did not affect 
renal or pancreatic GNMT (McMullen et al., 2002). 
RA is known to induce a gluconeogenic state which in turn alters methyl group 
metabolism through the induction of key gluconeogenic enzymes including 
phosphoenolpyruvate carboxykinase, the rate-limiting step of gluconeogenesis (Pan et al., 
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1990; Shin and McGrane 1997). Interestingly, GNMT is located primarily in gluconeogenic 
tissues implying a possible role in hormonal regulation. These modifications of GNMT 
activity by RA are thought to occur transcriptionally, however there is currently no report of 
a retinoic acid response element on the promoter region of GNMT (Pan, et al., 1990). 
Phosphorylation of GNMT has been shown to modulate activity of the enzyme. Wagner et 
al. found in vitro that phosphorylation, by cAMP-dependent protein kinase, of GNMT 
resulted in a 2-fold increase in the activity of the enzyme; however if 5-CH3 THF was first 
bound to GNMT, phosphorylation was inhibited as well as enzyme activity (1989). Further 
research needs to be conducted to exactly determine the mechanism by which retinoids alter 
methyl group metabolism. These factors that affect methyl group metabolism prompted the 
study in the following chapter. The study was conducted to determine how both a diabetic 
state and/or retinoid treatment alter methyl group metabolism. 
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CHAPTER 3 - MODULATION OF METHYL GROUP METABOLISM 
BY STREPTOZOTOCIN-INDUCED DIABETES AND ALL-trans-
RETINOIC ACID1 
A paper published in the Journal of Biological Chemistr/ 
Kristin M. Nieman3, Matthew J. Rowling4, Timothy A. Garrow5, and Kevin L. Schalinske3 
Abstract 
The hepatic enzyme glycine N-methyltransferase (GNMT) plays a major role in the 
control of methyl group and homocysteine metabolism. Because disruption of these vital 
pathways is associated with numerous pathologies, understanding GNMT control is 
important for evaluating methyl group regulation. Recently, gluconeogenic conditions have 
been shown to modulate homocysteine metabolism and treatment with glucocorticoids and/or 
all-trans-retinoic acid (RA) induced active GNMT protein, thereby leading to methyl group 
loss. This study was conducted to determine the effect of diabetes, alone and in combination 
with RA, on GNMT regulation. Both diabetes and RA increased GNMT activity 87% and 
148% respectively. Moreover, the induction of GNMT activity by diabetes and RA was 
reflected in its abundance. Cell culture studies demonstrated that pretreatment with insulin 
prevented GNMT induction by both RA and dexamethasone. There was a significant decline 
in homocysteine concentrations in diabetic rats, owing in part to a 38% increase in the 
abundance of the transsulfuration enzyme cystathionine ~-synthase (CBS); treatment of 
diabetic rats with RA prevented CBS induction. A diabetic state also increased the activity 
of the folate-independent homocysteine remethylation enzyme betaine-homocysteine S-
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methyltransferase (BHMT), whereas the activity of the folate-dependent enzyme methionine 
synthase (MS) was diminished 52%. In contrast, RA treatment attenuated the streptozotocin-
mediated increase in BHMT, whereas MS activity remained diminished. These results 
indicate that both a diabetic condition and RA treatment have marked effects on the 
metabolism of methyl groups and homocysteine, a finding that may have significant 
implications for diabetics and their potential sensitivity to retinoids. 
Introduction 
Methyl group and folate-dependent one-carbon metabolism are interrelated pathways 
that provide for the subsequent transmethylation of various molecules using S-
adenosylmethionine (SAM) 6. SAM, resulting from the adenylation of methionine, is the 
primary methyl donor in the body (Wagner 1995) (Figure 3.1). An adequate supply of 
methyl groups, via the diet or the folate-dependent one-carbon pool, and regulation of these 
pathways is essential in preventing associated pathologies such as cancer, vascular disease, 
and neural tube defects (Ross 2003; Kang et al., 1992; Scott et al., 1990). Glycine N-
methyltransferase (GNMT) is an abundant, tissue-specific protein that plays a key role in the 
regulation of hepatic methyl group metabolism by the enzymatic conversion of glycine and 
SAM to S-adenosylhomocysteine (SAH) and sarcosine (Wagner 1995; Kerr 1972; Yeo and 
Wagner 1994 ). GNMT functions to optimize the SAM/SAH ratio, an indicator of 
transmethylation potential, because SAH is a potent inhibitor of most SAM-dependent 
methyltransferases (Kerr 1972; Cantoni and Chiang 1980). Following hydrolysis of SAH, 
the resulting homocysteine can undergo remethylation to methionine, or be irreversibly 
catabolized by the transsulfuration pathway. Folate-dependent remethylation occurs with the 
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donation of a methyl group by 5-methyltetrahydrofolate (5-CH3-THF) through the action of 
B12-dependent methionine synthase (MS) (Shane and Stokstad 1985). In hepatic tissue, 
betaine derived from the oxidation of choline can also serve as a folate-independent source of 
methyl groups for homocysteine remethylation via the enzyme betaine-homocysteine S-
methyltransferase (BHMT). Transsulfuration to cysteine occurs through the activity of two 
vitamin B6-dependent enzymes. Initially, homocysteine is converted to cystathionine by the 
activity of cystathionine ~-synthase (CBS), and finally, y-cystathionase converts 
cystathionine to the amino acid cysteine (Jacobs et al., 2001). 
The regulation of hepatic GNMT represents an important mechanism for controlling 
both the folate-dependent supply of methyl groups as well as their utilization in SAM-
dependent transmethylation reactions. GNMT activity is regulated in response to changes in 
methyl group status as the result of allosteric inhibition of 5, 10-methylenetetrahydrofolate 
reductase (MTHFR) by SAM (Jencks and Matthews 1987; Kutzback and Stokstad 1967) and 
inhibition of GNMT by 5-CH3-THF (Wagner et al., 1985; Wagner et al., 1989), the 
enzymatic product of MTHFR. This allows methyl groups to be conserved under conditions 
of deficiency by decreasing GNMT activity, whereas elevations in its activity function to 
dispose of excess methyl groups. In addition to allosteric control, phosphorylation of GNMT 
represents another posttranslational mechanism to increase the activity of GNMT and 
regulate methyl group metabolism (Wagner et al., 1989). 
Recent studies have identified both nutritional and hormonal factors that alter 
methyl group metabolism by targeting key enzymes involved. All-trans-retinoic acid (RA) 
has been shown to induce hepatic GNMT activity and protein abundance, resulting in the loss 
of methyl groups for subsequent transmethylation reactions (McMullen et al., 2002; Ozias 
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and Schalinske 2003; Rowling et al., 2002; Rowling and Schalinske 2001). Moreover, 
dexamethasone (DEX) was just as effective as RA in the induction of GNMT activity in rat 
liver and hepatoma cells, and the coadministration of both DEX and RA induced GNMT in 
an additive fashion (Rowling and Schalinske). A diabetic state characterized by insufficient 
circulating concentrations of insulin and elevated levels of the counter-regulatory hormones, 
glucagon and glucocorticoids, has also been reported to alter enzymes involved in methyl 
group metabolism. An elevation in the activity of GNMT has been reported in alloxan-
induced diabetic sheep and rats (Yeo and Wagner 1994; Xue and Snoswell 1985); however, 
little is known about the mechanistic basis for this increase. Brosnan and coworkers have 
shown that under diabetic conditions, the catabolism of homocysteine was enhanced by 
transcriptional regulation of CBS and these changes were prevented by treatment with insulin 
(Jacobs et al., 1998; Jacobs et al., 2001; Ratnam et al., 2002). 
It has become overtly evident that both treatment with RA and a diabetic state 
independently cause aberrant modifications in methyl group metabolism. Although we have 
shown that DEX can significantly alter methyl group and homocysteine metabolism 
(Rowling and Schalinske 2003), the focus in this study was to evaluate these pathways in a 
diabetic rat model, alone and in combination with RA, as well as determine the effect of 
insulin on preventing these alterations. 
Experimental Procedures 
Chemicals 
Reagents were obtained as follows: S-adenosyl-L-[methyl-3H]methionine, Perkin 
Elmer Life Sciences (Boston, MA); chemiluminescence Western blotting detection reagents, 
Amersham Pharmacia (Piscataway, NJ); S-adenosyl-L-methionine and streptozotocin, Sigma 
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Chemical (St. Louis, MO); protease inhibitors, and RA, Calbiochem (Lamoille, CA); goat 
anti-mouse IgG horseradish peroxidase and goat anti-rabbit lgG horseradish peroxidase, 
Southern Biotechnology (Birmingham, AL). GNMT and CBS antibodies were kindly 
provided by Yi-Ming Chen, National Yang-Ming University, Taipei, Taiwan (Liu et al., 
2003) and Jan Kraus, University of Colorado Health Sciences Center, Denver, CO, 
respectively. All other chemicals were of analytical grade. 
Animals 
All animal experiments were approved by and conducted in accordance with Iowa 
State University Laboratory Animal Resources Guidelines. Male Sprague-Dawley (Harlan 
Sprague Dawley, Indianapolis, IN) rats (125-149g) were housed in individual plastic cages in 
a room with a 12-h light:dark cycle, and allowed free access to food and water. Rats were 
randomly assigned to treatment groups (6 rats per group) and acclimated to the control diet 
(Rowling and Schalinske 2003) for 5 d. Following the acclimation period, rats received a 
single intraperitoneal injection of either streptozotocin (STZ; 60 mg/kg body weight) in the 
vehicle (10 mM citrate buffer, pH 4.5) or the vehicle alone. The following day animals 
received a daily oral dose of RA (30 µmol/kg body weight) or vehicle (corn oil) alone. 
Following a 5-d treatment period with RA, rats were anesthetized and whole blood samples 
were collected via cardiac puncture. An aliquot of whole blood was used to assess blood 
glucose concentrations using a commercial kit (Sigma Chemical, St. Louis, MO), whereas 
the remaining blood was centrifuged at 4,000 x g for 6 min and the resulting plasma fraction 
was stored at -20°C for subsequent analysis of homocysteine concentrations. Liver samples 
were removed and homogenized in 4 volumes of ice-cold phosphate buffered ( 10 mM, pH 
7 .0) sucrose (0.25 M) containing 1 mM EDT A, 1 mM sodium azide, and 0.1 mM 
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phenylmethylsulfonyl fluoride (PMSF). Following centrifugation at 20,000 x g for 30 min, 
supernatants were stored at -70°C with lmM P-mercaptoethanol for subsequent enzymatic 
and protein abundance measurements. Total soluble protein concentrations were determined 
based on the method of Bradford (Bradford 1976) using a commercial kit (Coomassie Plus, 
Pierce Chemical, Rockford, IL) and bovine serum albumin as a standard. Additional liver 
samples were homogenized in 2 volumes of 0.4 M perchloric acid for the determination of 
SAM and SAH. 
Cell Culture 
Rat pancreatic AR42J and hepatoma H4IIE cells were obtained from the American 
Type Culture Collection (Manassas, VA). All cells were grown in 150-cm2 flasks in a 
humidified incubator with 5% C02 and a temperature of 37°C until they were 70-75% 
confluent. H4IIE cells were cultured in minimum essential medium containing 10% fetal 
bovine serum, penicillin (100 units/mL), and streptomycin (0.1 mg/mL). AR42J cells were 
grown in F-12K nutrient mixture containing 20% fetal bovine serum as well as penicillin and 
streptomycin. Cell lines received fresh media prior to the initiation of any treatments. H4IIE 
and AR42J cells were treated with either a vehicle of 0.01 % dimethyl sulfoxide (Me2SO, 
control), 10 µM RA, 0.1 µM DEX, or both RA and DEX as described previously (Rowling 
and Schalinske 2003). A parallel group of AR42J and H4IIE cells were preincubated with 
100 nM insulin for 24 h prior to the addition of RA and/or DEX. Following a 72-h 
incubation period, cells were detached using 0.25% trypsin/ lmM EDTA, washed with 
Hank's balanced salt solution, and lysed on ice in a buffer containing 10 mM HEPES (pH 
7.4), 10 mM sodium pyrophosphate, 50 mM sodium fluoride, 50 mM p-glycerophosphate, 5 
mM EDT A, 1 mM sodium orthovanadate, 2 mM benzamidine, 100 µg/mL leupeptin and 
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pepstatin, 250 µg/mL soybean trypsin inhibitor, 0.2 mM PMSF, 24 µg/mL p-
nitroguanidinobenzoate, and 0.5% Nonidet P-40. Following centrifugation at 16,000 x g for 
8 min, supematants were stored at -70°C for analysis of GNMT protein abundance. 
GNMT Activity Analysis 
The enzymatic activity of GNMT was determined using the method described by 
Cook and Wagner (Cook and Wagner 1984) with minor modifications, and performed in 
triplicate. The assay mixture (100 µL) consisted of 0.2 M Tris buffer (pH 9.0), 2 mM 
glycine, 5 mM dithiothreitol, 0.2 mM S-adenosyl-L-[methyl-3H]methionine, and was initiated 
with 250 µg protein followed by incubation at 25°C for 30 min. Trichloroacetic acid ( 10%) 
was added to terminate the reaction followed by the addition of activated charcoal and 
centrifugation (14,000 x g) to remove radiolabeled SAM. Aliquots of the supematants were 
removed for liquid scintillation counting. 
Determination of GNMT and CBS Protein Abundance 
GNMT protein abundance was determined using immunoblotting techniques as 
previously described (Rowling and Schalinske 2003). A 10-20% gradient SDS-
polyacrylamide gel was used to quantify the 32-kDa monomer subunit of GNMT. Following 
separation, proteins were transferred to a nitrocellulose membrane and incubated overnight at 
4°C with a 1:4,000 dilution of the monoclonal GNMT antibody (Liu et al., 2003). The 
membrane was then incubated with goat anti-mouse IgG horseradish peroxidase secondary 
antibody for 1 h at room temperature. CBS protein abundance was analyzed using a similar 
method as described above to separate the 63-kDa CBS subunit. A 1 :20,000 dilution of the 
polyclonal CBS antibody was used, followed by incubation with a goat anti-rabbit IgG 
horseradish peroxidase secondary antibody. GNMT and CBS protein abundance were 
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detected with chemiluminescence and exposed to Kodak X-Omat AR film. Densitometric 
analysis was performed using SigmaGel software (SPSS, Chicago, IL). For both GNMT and 
CBS, three samples from each treatment group were randomly chosen for analysis on a 
single immunoblot. 
Determination of Hepatic SAM and SAH Concentrations 
Perchloric acid-homogenates were centrifuged at 9,000 x g for 10 min and the 
resulting supematants were neutralized and applied to a C18 SepPak cartridge (Waters, 
Milford, MA) to obtain SAM and SAH (Fell et al., 1985; Schalinske and Steele 1996). SAM 
and SAH were separated and quantified by reversed-phase HPLC and UV detection (254 nm) 
using a mobile phase containing 30% methanol in 5 mM octane sulfonic acid (pH 4.0) 
operated isocratically at 1.2 mL/min. 
Analysis of BHMT and MS Activity 
BHMT activity was measured as previously described by Garrow (Garrow 1996). 
The standard BHMT assay contained 5 mM DL-homocysteine, 2 mM betaine (0.1 µCi), and 
40 µg total protein. The activity of MS was determined as previously described (Keating et 
al., 1985). The assay reaction mixture (200 µL) containing sodium phosphate buffer (105 
mM, pH 7.5), cyanocobalamin (0.12 µM), dithiothreitol (36 mM), SAM (0.3 mM), P-
mercaptoethanol (8.4 mM), homocysteine (8.25 mM), and [methyl- 14C]-THF (0.63 mM, 0.17 
µCi/µmol) was added to liver supematants, each sample containing 600 µg of protein, and 
incubated for 1 hat 37°C. Ice-cold water was added to terminate the reaction and the assay 
mixture was immediately applied to an AG 1-X8 (chloride form) resin columns. Effluent 
fractions (3 mL deionized water) were collected for subsequent liquid scintillation counting. 
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For both the BHMT and MS assay, homocysteine was prepared fresh daily from a 
thiolactone derivative. 
Plasma Homocysteine Analysis 
Total plasma homocysteine concentrations were determined using HPLC and 
fluorescence detection (Ubbink et al., 1991). For derivatization, 10% tributylphosphine in 
dimethylformamide was added to 300 µL plasma samples and subsequently incubated at 4°C 
for 30 min. The reaction was terminated with ice-cold trichloroacetic acid containing 1 mM 
EDT A. Following centrifugation at 1,000 x g for 5 min, supernatants were added to a 
solution containing borate buffer (0.125 M, pH 9.5), sodium hydroxide (1.55 M), and 4-
fluoro-7-sulfobenzofurazan (ammonium salt, 0.1 %). N-acetylcysteine (1 mM) was added to 
the plasma samples prior to derivatization as an internal standard. Samples were injected 
onto a µBondapak C 18 Radial-Pak column (Waters, Milford, MA) equilibrated in a mobile 
phase consisting of 4% acetonitrile in 0.1 M potassium phosphate buffer (pH 2.1). 
Statistical Analysis 
SigmaStat software (SPSS, Chicago, IL) was used for all statistical analyses. The 
mean values of each treatment group were subjected to a two-way ANOVA. When the 
ANOV A was significant (p < 0.05), means were compared using Fisher's least significant 
difference procedure. 
Results 
Rats Treated with STZ Resulted in Elevated Blood Glucose and Significantly Less 
Weight Gain Regardless of RA Treatment 
Cumulative weight gain for diabetic rats was 23 and 36% of respective non-diabetic 
values, whereas RA treatment was without effect (Table 3.1). STZ clearly induced a 
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diabetic state in rats as blood glucose concentrations were elevated 3.7-fold compared to 
control values. Rats treated with RA had no significant effect on circulating levels of glucose 
compared to control values, and RA attenuated the hyperglycemia exhibited by diabetic rats. 
Both Diabetes and RA-treatment Induced Active GNMT 
STZ-treated rats exhibited a 1.9-fold increase in hepatic GNMT activity compared to 
the control values (Figure 3.2A). RA increased GNMT activity 2.5-fold compared to control 
rats and was significantly greater than the degree of induction in STZ-treated rats. Hepatic 
GNMT activity was highest in the rats receiving both STZ and RA (2.6-fold), although this 
increase was not significantly different from RA treatment alone. The changes in GNMT 
activity in diabetic and RA-treated rats were also reflected in the abundance of the protein, 
where a 5.3- and 4.8-fold increase was observed, respectively (Figure 3.2B). Moreover, co-
administration of STZ and RA significantly induced GNMT protein abundance (6.8-fold) to 
a greater extent than either treatment alone. Thus, both RA treatment and a diabetic 
condition modulate the expression of active GNMT in rat liver. 
Induction of GNMT by RA and/or DEX was Prevented by Insulin Treatment 
As reported previously (Rowling and Schalinske 2003), both RA and DEX alone or in 
co-administration resulted in induction of the GNMT protein in H4IIE rat hepatoma cells 
(Figure 3.3). Incubating cells with insulin for 24 h prior to treatment with RA and/ or DEX 
prevented GNMT induction. Similarly, DEX-mediated induction of GNMT in AR42J cells 
was also prevented by insulin; however, RA was not an effective signal to induce GNMT in 
these cells. 
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STZ-treatment Reduced Plasma Homocysteine Concentrations and Induced CBS 
Abundance 
Plasma homocysteine concentrations were significantly reduced -48% in both groups 
of STZ-treated rats, regardless of RA administration (Figure 3.4). Although we have 
previously found that RA alone was effective at lowering circulating homocysteine levels 
(Ozias and Schalinske 2003), the 26% decrease observed under these experimental 
conditions did not reach statistical significance. The hypohomocysteinemia exhibited by 
diabetic rats appears to be due, in part, to a 38% increase in the abundance of CBS, the initial 
enzyme in the irreversible catabolism of homocysteine (Figure 3.5). However, CBS activity 
is regulated allosterically and thus, flux studies conducted in vivo would be required to 
evaluate the transsulfuration pathway. Interestingly, RA treatment of diabetic rats prevented 
CBS induction (Figure 3.5), even though plasma homocysteine concentrations remained 
diminished (Figure 3.4). 
STZ- and RA-treatments Differentially Stimulate Homocysteine Remethylation 
Enzymes 
In addition to transsulfuration, the reduced plasma homocysteine levels also appear to 
reflect changes in the activity of enzymes involved in homocysteine remethylation. BHMT 
activity was significantly increased 3.3-fold in diabetic rats, whereas the activity of MS was 
reduced 52% (Table 3.2). RA did not significantly alter either enzyme, although there was a 
trend (p = 0.061) for increased MS activity, similar to our previous observations (Ozias and 
Schalinske 2003). RA was effective at reducing the activity of BHMT in diabetic rats, but 
did not prevent the STZ-mediated decrease in MS activity. 
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STZ-mediated Elevations in the Hepatic Concentrations of SAM and SAH were 
Prevented by RA Treatment 
A diabetic condition resulted in a significant increase in the hepatic concentrations of 
SAM ( 169%) and SAH (90% ). Although RA treatment did not significantly alter SAM and 
SAH concentrations in non-diabetic rats, it did prevent their accumulation in diabetic animals 
(Table 3.3). Because SAM and SAH are allosteric regulators of a number of enzymes 
involved in folate, methyl group, and homocysteine metabolism, it is difficult to determine 
the collective metabolic effect of these changes in diabetic rats in the absence of flux 
measurements using isotopic tracers. 
Discussion 
Methyl groups, homocysteine, and the folate-dependent one-carbon pool represent 
interrelated metabolic processes that are important in health and disease. Because GNMT is 
a vital regulatory protein that functions to control the supply and utilization of methyl groups, 
it is paramount to understand how nutritional and/ or hormonal factors modulate its 
expression. Our earlier work demonstrated that RA and DEX were independent signals to 
induce active GNMT in rat liver and in cultured hepatoma cells (Rowling and Schalinske 
2003). Here, we have extended these findings by demonstrating that a diabetic condition, 
mediated by treatment with STZ, also has a profound impact on the activity of hepatic 
GNMT. Previous rat studies using alloxan-induced diabetes reported similar increases (85%) 
in GNMT activity (Yeo and Wagner 1994), whereas treatment with glucagon were less 
pronounced (23%) (Jacobs et al., 2001); however, the mechanistic basis for this increase in 
GNMT activity has not been thoroughly explored. A novel aspect of our studies 
demonstrates that for both diabetes and RA, the abundance of GNMT protein was markedly 
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elevated, indicating that GNMT was regulated by transcriptional and/or translational 
mechanisms, or possibly at the level of degradation of the protein. It is not known if 
regulation of GNMT expression in a diabetic state is the result of an increase in 
glucocorticoid levels or a lack of insulin. The cell culture studies shown here clearly 
demonstrate that pretreatment with insulin prevented GNMT induction by both STZ and RA. 
It will be important in future studies to more fully characterize this diabetic condition with 
alterations in methyl group metabolism. Interestingly, the responsiveness of GNMT 
expression to RA and DEX appears to be cell-type specific. We have found in other studies 
that DEX was a more universal signal than RA for GNMT induction across a number of 
tissues and cell lines, including those that do not express detectable GNMT, such as the 
human hepatoma cell line HepG2 7• 
It is not clear how RA, DEX, and/or a diabetic state alter the expression of GNMT. 
Previous studies on the regulation of GNMT activity have found it to be at the 
posttranslational level by phosphorylation and allosteric inhibition by 5-CH3-THF (Wagner 
et al., 1985; Wagner et al., 1989; Balaghi et al., 1993; Cook et al., 1989). Based on the 
known actions of glucocorticoids and RA with respect to regulation of gene expression, it is 
likely that the induction of GNMT is the result of increased transcription. In support of this 
hypothesis, we have found that pretreatment of hepatoma cells with actinomycin D prevented 
GNMT induction by DEX and RA, and abundance of the protein appears to reflect changes 
in its synthesis rate 8. However, GNMT has not been reported to contain a retinoic acid- nor 
a glucocorticoid-response element in its promoter region (Ogawa et al., 1998). Therefore, it 
is likely that additional intracellular signals are required to directly mediate regulation of 
GNMT expression. Nonetheless, we cannot exclude the possibility that increases in 
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phosphorylation of the protein has a role in increasing GNMT activity, particularly as 
glucagon and glucocorticoids can exert their action via alterations in protein kinase activity. 
Homocysteine concentrations reflect the collective balance between production, from 
SAM-dependent transmethylation reactions, remethylation to methionine, and catabolism via 
the transsulfuration pathway. As has been reported (Jacob et al., 1998; Jacob et al., 2001), 
we also found that a diabetic state was characterized by a reduction in circulating 
homocysteine levels. This change in homocysteine homeostasis appears to reflect an 
increase in the activity of BHMT and the abundance of CBS, even though the activity of MS 
was reduced. Similarly, previous diabetes/hyperglucagonemia studies have attributed the 
hypohomocysteinemia to up-regulation of CBS and y-cystathionase, whereas the activity of 
hepatic BHMT and MS were not significantly altered (Jacob et al., 1998; Jacob et al., 2001; 
Ratnam et al., 2002). However, in the absence of flux studies it is difficult to determine 
homocysteine catabolism, because CBS is regulated allosterically by other factors such as 
SAM, a known allosteric stimulator of CBS activity (Finkelstein and Martin 1984). In 
support of the increase in CBS abundance that we reported, we also found that the hepatic 
concentration of SAM was elevated, in agreement with previous studies using 
hyperglucagonemic rats (Jacobs et al., 2001). Elevations in hepatic SAM levels may be the 
result of increased expression of methionine adenosyltransferase, as it is up regulated by 
glucocorticoids (Gil et al., 1997). An increase in hepatic SAM concentrations would also be 
expected to reduce 5-CH3-THF levels as a result of allosteric inhibition of MTHFR (Jencks 
and Matthews 1987; Kutzback and Stokstad 1967). The lack of 5-CH3-THF acting as an 
inhibitory ligand for GNMT (Wagner et al., 1985), like phosphorylation, may be a 
contributing factor for the increase in its activity in diabetic rats. An interesting aspect of our 
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work was that the administration of RA to diabetic rats prevented CBS induction and SAM 
accumulation, and partially reduced the activity of BHMT, whereas MS activity was 
unaffected. In contrast to diabetes, RA alone had no affect on CBS abundance or the activity 
of BHMT and MS, although we have found in previous studies that RA does increase MS 
when provided for a longer period of time (Ozias and Schalinske 2003). However, it should 
be noted that the activity and abundance of GNMT remained elevated in rats treated with 
RA. This further illustrates the need for metabolic flux measurements under in vivo 
conditions to determine the outcome of these interactions. 
The implications of these results for humans are profound, as diabetes and its 
complications are a significant health problem and the use of pharmacological retinoid 
compounds has risen dramatically in recent years (Wysowski et al., 2002). In addition to 
folate, optimal metabolism of methyl groups and homocysteine is dependent on a number of 
B-vitamins including B12, B6, and riboflavin, as well as an adequate source of methyl groups 
such as methionine and choline. Moreover, it is well known that the human population has a 
significant prevalence of polymorphic enzymes important in methyl group, homocysteine, 
and folate-dependent one-carbon metabolism (Loktionov 2003). Taken together, these 
nutritional, genetic, and hormonal factors underscore the need for understanding the 
relationship between these metabolic pathways and diabetes. As most type I diabetics 
control their disease by the use of insulin, there nonetheless are likely many individuals that 
do not adequately monitor their condition. Moreover, many of the changes noted in our 
study were recently demonstrated in a type II diabetes (Zucker diabetic fatty rat) model, 
including an increase in hepatic CBS, BHMT, and SAM (Wijekoon et al., 2004). 
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Figure Legends 
Figure 3.1. Hepatic methyl group, homocysteine, and folate-dependent one-carbon 
metabolism. Methyl groups, as S-adenosylmethionine (SAM), are utilized in numerous 
transmethylation reactions (X ~ X-CH3), such as the methylation of nucleic acids, 
phospholipids, and neurotransmitters. Following donation of its methyl group, SAM is 
converted to S-adenosylhomocysteine (SAH) which is subsequently hydrolyzed to 
homocysteine. The irreversible catabolism of homocysteine via transsulfuration occurs 
through the activity of cystathionine P-synthase (CBS) and y-cystathionase. Alternatively, 
homocysteine can be remethylated by the folate-independent enzyme, betaine-homocysteine-
S-methyltransferase (BHMT), or the folate-dependent enzyme, methionine synthase (MS). 
Methyl groups from the folate-dependent one-carbon pool for homocysteine remethylation 
originate primarily from serine and the subsequent action of 5,10-methylenetetrahydrofolate 
reductase (MTHFR), the enzyme that irreversibly reduces the methylene group of 5,10-CH2-
THF to 5-CH3-THF, as opposed to its use in thymidylate synthesis. Glycine N-
methyltransferase (GNMT) regulates the supply and utilization of methyl groups. As shown 
by the dashed line, SAM is an allosteric inhibitor of MTHFR, whereas 5-CH3-THF is an 
allosteric inhibitor of GNMT activity. Additional abbreviations used are: DMG, 
dimethylglycine; THF, tetrahydrofolate. 
Figure 3.2. Induction of hepatic glycine-N-methyltransferase (GNMT) activity and 
abundance in streptozotocin (STZ)-mediated diabetic and all-trans-retinoic acid (RA)-
treated rats. Diabetic (single dose of STZ, 60 mg/kg body weight) rats were treated daily 
with RA (30 µmol/kg body weight) for 5 d. Liver samples were removed and the activity 
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and abundance of GNMT was determined as described under Experimental Procedures. A, 
GNMT enzyme activity in diabetic and non-diabetic rats following administration of RA or 
com oil. Data are expressed as means± S.E. (n = 6) and bars denoted with different letters 
are significantly different (p < 0.05). B, GNMT protein abundance in diabetic and non-
diabetic rats following administration of RA or corn oil. A monoclonal GNMT antibody (22) 
was used for Western blot analysis and a representative immunoblot is shown. Data are 
expressed as means± S.E. (n = 3) and bars denoted with different letters are significantly 
different (p < 0.05). 
Figure 3.3. Regulation of glycine N-methyltransferase (GNMT) expression in rat 
hepatoma and pancreatic cell lines. Rat hepatoma H4IIE (upper panel) and pancreatic 
AR42J (lower panel) cells were treated with the following: 0.01 % Me2SO (control, lane 1), 
10 µM all-trans-retinoic acid (RA, lane 2), O.lµM dexamethasone (DEX, lane 3), or both RA 
and DEX (lane 4). A parallel group of cells were preincubated with 100 nM insulin for 24 h 
prior to their respective treatments (lanes 5-8). Following a 72-h incubation period, cells 
were lysed and used to determine GNMT abundance via Western blotting as described under 
"Experimental Procedures". 
Figure 3.4. Plasma homocysteine concentrations in streptozotocin (STZ)-mediated 
diabetic and all-trans-retinoic acid (RA)-treated rats. Plasma samples from the same rats 
as described for Fig. 1 were obtained for the determination of total homocysteine 
concentrations by HPLC and fluorometric detection as described under "Experimental 
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Procedures". Data are expressed as means ± SEM (n = 6); bars with different letters are 
significantly different (p < 0.05). 
Figure 3.5. The abundance of cystathionine P-synthase (CBS) was elevated in 
streptozotocin (STZ)-mediated diabetic rats and abrogated following treatment with 
all-trans-retinoic acid (RA). Hepatic tissue samples from the same rats as described for Fig. 
1 were used to determine CBS abundance by Western blot analysis as described under 
"Experimental Procedures". A representative immunoblot is shown above the bar graph. 
Data are means± S.E. (n = 3); bars denoted with different letters are significantly different (p 
< 0.05). 
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Tables & Figures 
Table 3.1 
Cumulative weight gain and blood glucose concentrations in rats 
treated with streptozotocin (STZ) and/or all-trans-retinoic acid (RA) 
Values are expressed as mean± S.E. (n = 6). Values within a column 
with different letter superscripts are significantly different, p < 0.05. 
Weight gain Blood glucose 
g mg/dL 
Control 77 ± 2 a 147 ± 17 a 
STZ 18 ± 3 b 539±19b 
RA 73 ± 1 a 165 ± 17 a 
STZ+RA 26 ± 5 b 435 ± 51 c 
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Table 3.2 
Activity of remethylation enzymes methionine synthase (MS) and 
betaine-homocysteine S-methyltransferase (BHMT) in the livers of 
rats treated with streptozotocin (STZ) and/or all-trans-retinoic acid 
(RA) 
Values are expressed as mean± S.E. (n = 6). Values within a column 
with different letter superscripts are significantly different, p < 0.05. 
BHMT MS 
units/mg protein pmollmin · mg protein 
Control 40 ± 3 a 86 ± 11 a 
STZ 132 ± 11 b 41±5 b 
RA 51±4 a 119±19a 
STZ+RA 100 ± 8 c 36 ± 6 b 
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Table 3.3 
Hepatic concentrations of S-adenosylmethionine (SAM) and S-
adenosylhomocysteine (SAH) from rats treated with streptozotocin 
(STZ) and/or all-trans-retinoic acid (RA) 
Values are expressed as mean± S.E. (n = 5-6). Values within a column 
with different letter superscripts are significantly different, p < 0.05. 
SAM SAH SAM/ SAH 
nmol/g liver 
Control 42.7 ± 2.3 a 34.9 ± 2.1 a 1.24 ± 0.08 a 
STZ 114.9 ± 22.5 b 66.3 ± 10.2 b 1.77 ± 0.34 a 
RA 38.9 ± 3.1 a 34.5 ± 4.1 a 1.20 ± 0.15 a 
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CHAPTER 4 - GENERAL CONCLUSIONS 
Folate, homocysteine, and one-carbon metabolism function in concert to provide 
activated one-carbon units in the modification and synthesis of essential biological 
compounds. Therefore, interruptions in these vital pathways may have serious implications 
in health and disease. GNMT is a key regulatory mechanism in the supply of methyl groups 
for SAM-dependent transmethylation reactions, whereas inappropriate activation of this 
enzyme may lead to loss of methyl groups and in turn pathological conditions. 
In this thesis we have further elucidated modifications in methyl group metabolism in a 
streptozotocin-induced diabetic state, characterized by reduced circulating insulin and 
elevated counterregulatory hormones, essentially a gluconeogenic state. RA has also been 
identified as having the ability to induce a gluconeogenic state by increasing the expression 
of key enzymes involved, and GNMT has been shown to be activated during gluconeogenic 
conditions (Pan et al., 1990; Shin and McGrane 1998). The study revealed an induction of 
hepatic GNMT activity and abundance in a diabetic state. The induction of GNMT may be a 
result of excess SAM inhibiting MTHFR which decreases 5-CH3 THF, and alleviates negative 
allosteric regulation of GNMT. However, RA administration prevented elevated SAM 
accumulation in diabetic rats. The greatest elevation in the abundance was in diabetic rats 
treated with RA, indicating GNMT may be regulated at the level of transcription, translation, 
or post-translation due to reduced protein degradation. Further, we have shown in cell 
culture that induction of GNMT followed by treatment with glucocorticoids, which tend to be 
elevated in a diabetic state, was prevented by pretreatment with insulin. 
We have also shown that a diabetic state results in reduced circulating homocysteine 
concentrations which may be due to increased transsulfuration and remethylation. CBS 
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which commits homocysteine to transsulfuration revealed induction of the protein in a 
diabetic state. A diabetic state also caused an increase in the activity of the folate-
independent remethylation enzyme, BHMT. This reduction in homocysteine has been 
evident in other studies as a result of increased transsulfuration; however remethylation 
enzymes have not been altered in previous reports (Jacobs et al., 2001). 
Approximately 5.9% of the U.S. population is affected by diabetes (Franz 2000). The 
results reported in this thesis may have significant implications for complications associated 
with the disease specifically in those individuals that use retinoids therapeutically. The 
therapeutic use of retinoids has also increased approximately 2.5-fold in the last decade 
(Wysowski et al., 2002) further indicating a need to understand completely, the ways in 
which diabetes effects methyl group metabolism. 
Many questions remain and need to be addressed by future research. First, the 
mechanism by which GNMT is up-regulated is still unknown. Based on how glucocorticoids 
and RA act leads us to believe regulation occurs at the level of transcription. However, there 
is currently no known RA- or glucocorticoid-response element on the promoter region of 
GNMT (Ogawa, et al., 1998). Further research to determine if these alterations emerge as a 
result of increased circulating counterregulatory hormones or lack of insulin, will continue to 
define the effect of a diabetic state on these metabolic pathways. Secondly, further research 
needs to be directed at determining if folate status alters the effects seen in a diabetic state. 
As mentioned previously, 5-CH3THF provides allosteric regulation for GNMT. It would be 
interesting to investigate modulation of methyl group metabolism in a folate-deficient 
diabetic model, as well as a diabetic model supplemented with folate. Finally, it will be 
imperative to evaluate whether these perturbations in methyl group metabolism can be 
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prevented by insulin treatment. Studies in cell culture would indicate so, but further research 
should be directed to the possibly prevention with insulin in vivo. 
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